ATGen develops detection kit for new flu infections

Published: 2010-02-10 06:57:00

Updated: 2010-02-10 06:57:00

A local biopharmaceutical company ATGen Co. Ltd. recently announced the launch of a new influenza A H1N1/2009 (FLUAb) in providing solutions for the global surveillance of the new flu pandemic.

ATGen’s new kit enables both the highly sensitive and specific detection of the novel Influenza A/H1...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK